Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (stage IIIB/C/D-IV M1a) Melanoma with Injectable Disease
Clinical trial NCT04330430 · COMPLETED
Trial details
- NCT number
- NCT04330430
- Sponsor
- The Netherlands Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-08
- Primary completion
- 2023-04-09
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.